In a recent preclinical study, the pharmacological inhibition of NLRP3 through miRNA reduced the tumor growth and the immune-resistance in breast cancer-bearing mice through ASC/IL-1/IL-18 pathways; these data provide new clinical insights for breast cancer management [57]. This evidence concerns the gene IL1B and breast carcinoma.